Clinical Significance of Precise Hyperthermic Intraperitoneal Chemotherapy Up-regulation RP11-356I2.2 Restraining the Occurrence and Development of Gastric Cancer

In order to study the therapeutic effect and possible mechanism of Precise Hyperthermic Intraperitoneal Chemotherapy (HIPEC) on gastric cancer, the expression of RP11-356I2.2 in gastric cancer cell lines and tissues was detected by real-time fluorescence quantitative PCR (RT-PCR). Chi-square test was used to analyze the correlation between the expression and clinic pathological parameters. Western blotting was used to detect the expression of RP11-356I2.2 and tumor suppressor geneKLF17 after precise HIPEC. The effect of RP11-356I2.2 on KLF17 protein was observed and expressed by Western blotting and immunofluorescence. COX regression model was used to analyze the relationship between the expression of RP11-356I2.2 and KLF17 and the prognosis of patients with gastric cancer. The results of RT-PCR showed that RP11-356I2.2 was lower in BGC-823, MKN-28, MGC-803, SGC-7901 and MKN-45 than normal stomach cells GES-1 (P<0.05). Its expression level was inversely proportional to the malignant degree of gastric cancer. Meanwhile, stable expression SGC-7901/RP11-356I2.2 cell line was established, western blotting and immunofluorescence showed the up-regulation of KLF17 protein. The expression of RP11-356I2.2 and tumor suppressor gene KLF17 increased after precise HIPEC. After 5 years of follow-up, the Disease-Survival rate (DFS) and total Survival rate (OS) of KLF17 high expression group were 9.7 and 14.2 months respectively, which were significantly longer (P<0.05) than KLF17 low expression group, DFS (5.4 months) and OS (10.2 months). The up-regulation of KLF17 protein by up-regulation of RP11-356I2.2 in precise intraperitoneal hyperthermic chemotherapy may be one of the mechanisms of HIPEC inhibiting gastric cancer.